FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
January 04 2022 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique
Conterno, Chief Executive Officer, will participate in a fireside
chat at the H.C. Wainwright Bioconnect Virtual Conference taking
place January 10-13. The on-demand webcast of the session will be
available on January 10 at 7:00am EST.
The audio webcast of the event will be available on the “Events
& Presentations” section of the FibroGen Investor webpage at
www.fibrogen.com. A replay will be available for approximately 30
days.
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines for the treatment of unmet needs. The
Company is currently developing and commercializing roxadustat, an
oral small molecule inhibitor of HIF prolyl hydroxylase activity
for anemia associated with chronic kidney disease (CKD), anemia
associated with myelodysplastic syndromes (MDS), and for
chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in clinical development for the treatment
of idiopathic pulmonary fibrosis (IPF), locally advanced
unresectable pancreatic cancer (LAPC), and Duchenne muscular
dystrophy (DMD). FibroGen recently expanded its research and
development portfolio to include product candidates in the
immuno-oncology and autoimmune space. For more information, please
visit www.fibrogen.com.
Contact:FibroGen, Inc.
Investors:Michael Tung, M.D.Corporate Strategy
/ Investor Relationsmtung@fibrogen.com
Media:Meichiel KeenanPublic
Affairsmkeenan@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024